# EDGAR Filing Document

**Accession Number:** 0001133818
**File Stem:** 0001104659-23-032779
**Filing Date:** 2023-3
**Character Count:** 27168
**Document Hash:** 0d8086958ee6ac14e5fa133aa0ce40d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-032779.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001104659-23-032779

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**EFFECTIVENESS DATE**: 20230315

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-PATH HOLDINGS INC
- **CENTRAL INDEX KEY:** 0001133818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 870652870
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270561
- **FILM NUMBER:** 23735377

**BUSINESS ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401
- **BUSINESS PHONE:** (832) 742-1357

**MAIL ADDRESS:**
- **STREET 1:** 4710 BELLAIRE BOULEVARD
- **STREET 2:** SUITE 210
- **CITY:** BELLAIRE
- **STATE:** TX
- **ZIP:** 77401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OGDEN GOLF CO CORP
- **DATE OF NAME CHANGE:** 20010205

**As filed with the Securities and Exchange Commission on March 15, 2023**

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**BIO-PATH HOLDINGS, INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **87-0652870** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification No.)** |

---

**4710 Bellaire Boulevard, Suite 210** 

**Bellaire, Texas 77401** 

**(832) 742-1357**

**(Address of principal executive offices)** 

**BIO-PATH HOLDINGS, INC. 2022 STOCK INCENTIVE PLAN** 

**(Full title of the plan)** 

***Copies to:***

---

| | |
|:---|:---|
|  **Peter H. Nielsen<br> President and Chief Executive Officer**<br> **Bio-Path Holdings, Inc.**<br> **4710 Bellaire Boulevard, Suite 210** <br> **Bellaire, Texas 77401** <br> **(832) 742-1357**<br>| **William R. Rohrlich, II**<br> **Winstead PC**<br> **600 Travis Street**<br> **Suite 5200**<br> **Houston, Texas 77002**<br> **(281) 681-5912**<br>|

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The document(s) containing the information required by Part I of Form S-8 will be sent or given to employees as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). Such documents need not be filed with the Securities and Exchange Commission (the "Commission"), either as part of the Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirement of Section 10(a) of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by Bio-Path Holdings, Inc. (the "Company") with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company's [Annual Report on Form 10-K for the fiscal year ended December 31, 2021](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022003298/bpth-20211231x10k.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company's Quarterly Reports on Form 10-Q for the quarters ended [March 31](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022008980/bpth-20220331x10q.htm) , [June 30](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022013644/bpth-20220630x10q.htm) and [September 30, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022017789/bpth-20220930x10q.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company's Current Reports on Form 8-K filed with the Commission
on [February 18, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022001442/bpth-20220214x8k.htm) ; [February 25, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022002156/bpth-20220223x8k.htm) ; [April 6, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000155837022005126/bpth-20220331x8k.htm) (other than information furnished under Item 7.01 and exhibits related thereto); [November 9, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000110465922116216/tm2230081d1_8k.htm) (other than information furnished under Item 7.01 and exhibits related thereto) and [December 20, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_8k.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company's Definitive Proxy Statement on Schedule 14A relating to
the Company's 2022 Annual Meeting of Stockholders, filed [October 28, 2022](https://www.sec.gov/Archives/edgar/data/1133818/000155837022015590/tmb-20221215xdef14a.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company's description of common stock contained in the Company's
registration statement on Form 8-A filed with the SEC on [March 5, 2014](https://www.sec.gov/Archives/edgar/data/1133818/000114420414013489/v370623_8a12b.htm) , as updated by the Company's Current Report on Form 8-K filed
with the SEC on [January 6, 2015](https://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_8k.htm) .

All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the 1934 Act, subsequent to the date of this Registration Statement shall be deemed to be incorporated herein by reference and to be a part hereof from the date of filing of such documents until such time as there shall have been filed a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold at the time of such amendment.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.** 

Not applicable.

**Item 6. Indemnification of Directors and Officers.** 

Section 102(b)(7) of the Delaware General Corporation Law (the "DGCL") permits a corporation to eliminate or limit the personal liability of its directors to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Company's certificate of incorporation provides that to the fullest extent elimination or limitation of personal liability of directors is permitted by the DGCL, no director of the Company shall be liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director.

Section 145 of the DGCL permits a corporation to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is party or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.

The Company's first amended and restated bylaws and certificate of incorporation provide that each person (and the heirs, executors or administrators of such person) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or officer of the Company shall be indemnified and held harmless by the Company to the fullest extent permitted by applicable law. The Company's certificate of incorporation also states that the Company will pay or reimburse the reasonable expenses incurred in defending any such action, suit or proceeding in advance of its final disposition if the Company has received an undertaking by the person receiving such payment or reimbursement to repay all amounts advanced if it should be ultimately determined that he or she is not entitled to be indemnified.

The Company has entered into indemnification agreements with each of its directors. The contractual rights to indemnification provided by these indemnity agreements are subject to the limitations and conditions specified in such agreements.

The effect of the foregoing is to require the Company to indemnify its officers and directors for any claim arising against such persons in their official capacities if such person acted in good faith and in a manner that he or she reasonably believed to be in or not contrary to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Company's directors and officers, the Company has been advised that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

We have directors and officers insurance which includes insurance for claims against these persons brought under securities laws.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| [4.1](https://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_8k.htm) | [Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed on January 6, 2015).](https://www.sec.gov/Archives/edgar/data/1133818/000114420415000776/v398162_8k.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm) | [Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 9, 2018).](https://www.sec.gov/Archives/edgar/data/1133818/000114420418006765/tv485337_ex3-1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm) | [Certificate of Amendment to the Certificate of Incorporation of Bio-Path Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on January 16, 2019).](https://www.sec.gov/Archives/edgar/data/1133818/000114420419001872/tv511127_ex3-1.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm) | [First Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 7, 2017).](https://www.sec.gov/Archives/edgar/data/1133818/000114420417031532/v468617_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-1.htm) | [Bio-Path Holdings, Inc. 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 20, 2022).](https://www.sec.gov/Archives/edgar/data/1133818/000110465922128653/tm2233060d1_ex10-1.htm) |
| [5.1+](tm239511d1_ex5-1.htm) | [Opinion of Winstead PC.](tm239511d1_ex5-1.htm) |
| [23.1+](tm239511d1_ex23-1.htm) | [Consent of Ernst & Young LLP.](tm239511d1_ex23-1.htm) |
| [23.3+](tm239511d1_ex5-1.htm) | [Consent of Winstead PC (contained in Exhibit 5.1).](tm239511d1_ex5-1.htm) |
| [24.1+](#a_001) | [Power of Attorney (included on signature page of this Registration Statement).](#a_001) |

---

+ Filed herewith.

**Item 9. Undertakings.** 

(a) The undersigned Company hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) to include any prospectus required by Section 10(a)(3) of the 1933 Act;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;

(iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in the Registration Statement;

 

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the 1934 Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the 1933 Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Company hereby undertakes that, for purposes of determining liability under the Securities Act, each filing of the Company's annual report pursuant to section 13(a) or section 15(d) of the 1934 Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bellaire, State of Texas, on March 15, 2023.

---

| | |
|:---|:---|
| **BIO-PATH HOLDINGS, INC.** | **BIO-PATH HOLDINGS, INC.** |
| By: | /s/ Peter H. Nielsen |
|  | Peter H. Nielsen |
|  | President |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |
|  | Chief Financial Officer |
|  | (Principal Financial Officer and Principal Accounting Officer) |

---

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter H. Nielsen his or her true and lawful attorney-in-fact, with the power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities, in the locations and on the dates indicated.

---

| | |
|:---|:---|
| /s/ Peter H. Nielsen |  |
| Peter H. Nielsen | March 15, 2023 |
| President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) and Director |  |
| /s/ Heath W. Cleaver |  |
| Heath W. Cleaver | March 15, 2023 |
| Director |  |
| /s/ Paul D. Aubert |  |
| Paul D. Aubert | March 15, 2023 |
| Director |  |
| /s/ Aline Sherwood |  |
| Aline Sherwood | March 15, 2023 |
| Director |  |
| /s/ Douglas P. Morris |  |
| Douglas P. Morris | March 15, 2023 |
| Director |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm239511d1img001.jpg) | Austin I Charlotte I Dallas I Fort Worth I Houston I New York I San Antonio I The Woodlands |

---

March 15, 2023

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard, Suite 210<br> Bellaire, Texas 77401

Ladies and Gentlemen:

We have acted as legal counsel to Bio-Path Holdings, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the filing with the Securities and Exchange Commission (the "<u>Commission</u>") of a registration statement on Form S-8 (the "<u>Registration Statement</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the registration of up to 1,300,000 shares (the "<u>Shares</u>") of the Company's common stock, par value $0.001 per share, to be issued by the Company pursuant to the Bio-Path Holdings, Inc. 2022 Stock Incentive Plan (the "<u>Plan</u>").

In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement, (ii) the Plan, (iii) the Certificate of Incorporation of the Company, as currently in effect, (iv) the First Amended and Restated Bylaws of the Company, as currently in effect, and (v) such other records, certificates and documents as we have deemed appropriate or necessary for the purposes of this opinion. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates of public officials, certificates of officers or other representatives of the Company and others, and such other documents, certificates and records as we have deemed necessary or appropriate as a basis for the opinion set forth herein.

In our examination, we have assumed and have not verified (i) the legal capacity of all natural persons; (ii) the genuineness of all signatures (other than persons signing on behalf of the Company); (iii) the authenticity of all documents, certificates and instruments submitted to us as originals; (iv) the conformity with the originals of all documents supplied to us as copies; (v) the accuracy and completeness of all corporate records and documents made available to us by the Company; and (vi) that the foregoing documents, in the form submitted to us for our review, have not been altered or amended in any respect material to our opinions stated herein. We have relied as to factual matters upon certificates from officers of the Company and certificates and other documents from public officials and government agencies and departments and we have assumed the accuracy and authenticity of such certificates and documents. We have also assumed that, at or prior to the time of the issuance and delivery of any Shares, that there will not have occurred any change in law, change in the Company's Certificate of Incorporation, or further action by the Company's board of directors, in each case affecting the validity of the issuance of the Shares.

Based on the foregoing and subject to the limitations, qualifications and assumptions set forth herein, we are of the opinion that the Shares have been duly authorized and, when issued in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.

Our opinions herein are expressed solely as to the Delaware General Corporation Law (including, to the extent applicable, Delaware statutory and constitutional provisions and reported judicial decisions interpreting the foregoing). We express no opinion as to the laws of any other jurisdiction. The opinion expressed herein is given as of this date, and we do not undertake to supplement this opinion with respect to any events or changes occurring subsequent to the date of this letter. The opinion expressed in this letter is provided as a legal opinion only and not as any guarantee or warranty of the matters discussed herein, and such opinion is strictly limited to the matters stated herein, and no other opinion may be implied therefrom.

Bio-Path Holdings, Inc.<br> March 15, 2023<br> Page 2

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are "experts" within the meaning of Section 11 of the Securities Act or within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Winstead PC |
| Winstead PC |

---

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 pertaining to the 2022 Stock Incentive Plan of Bio-Path Holdings, Inc., of our report dated March 10, 2022, with respect to the consolidated financial statements of Bio-Path Holding, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

---

| |
|:---|
| /s/ Ernst & Young LLP |
| Houston, Texas |
| March 15, 2023 |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**Bio-Path Holdings, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security <br> Type** | **Security <br> Class<br> Title** | **Fee <br> Calculation <br> Rule** | **Amount <br> Registered<br> (1)** | **Proposed <br> Maximum <br> Offering <br> Price Per <br> Unit (2)** | **Maximum <br> Aggregate <br> Offering<br> Price** | **Fee <br> Rate** | **Amount of <br> Registration <br> Fee** |
| Fees to Be Paid (1) | Equity | Common Stock, par value $0.001 per share | Other (2) | 1300000 (3) | $1.4605 | $1898650 | 0.00011020 | $209.23 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |
| Carry Forward Securities |  |  |  |  |  |  |  |  |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $1898650 |  | $209.23 |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  | $0.00 |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $209.23 |

---

(1) Pursuant to Rule 416, this Registration Statement is deemed to include additional shares of common stock issuable under the terms of the Bio-Path Holdings, Inc. 2022 Stock Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction.

(2) Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) and (h) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), based upon the average of the high and low prices of Bio-Path Holdings, Inc.'s common stock as reported on the Nasdaq Capital Market on March 13, 2023.

(3) Consists of shares of common stock issuable in respect of awards to be granted under the Bio-Path Holdings, Inc. 2022 Stock Incentive Plan.